to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
Novel molecular targeted therapies for refractory thyroid cancer.
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.